IPO registrations (S-1, F-1) · Registrants
Oyster Point Pharma, Inc.
- SEC CIK
- 1720725 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2019-10-04, last 2020-05-14; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2019-10-31; declared effective 2019-10-30
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 202 CARNEGIE CENTER, SUITE 106, Princeton, NJ 08540
- EIN
- 81-1030955
- EDGAR entity type
- operating
- Insiders and CEO pay
- Oyster Point Pharma, Inc. on the corporate pages
Offering terms
- Proposed price range
- $16.00–$18.00 per share (S-1/A filed 2019-10-21)
- Final price
- $16.00 per share, within the range (424B4 filed 2019-10-31, an initial public offering)
- Shares sold
- 5,000,000
- Gross proceeds
- $80,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol OYST
- Lead underwriters
- J.P. Morgan; Cowen; Piper Sandler
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Oyster Point Pharma, Inc. Fuzzy (name and state)
- Form 5500 plan sponsor: OYSTER POINT PHARMA, INC. EXACT (EIN (EXACT))
- Federal award recipient: OYSTER POINT PHARMA, INC Fuzzy (name and state)
- Form D issuer: Oyster Point Pharma, Inc. EXACT (CIK (EXACT))
- SEC filer: Oyster Point Pharma, Inc. EXACT (CIK (EXACT))
- Person page: Michael G Atieh Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 11
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-10-04 | S-1 | S-1 (registration) | Oyster Point Pharma, Inc. | 0001193125-19-262771 ↗ |
| 2019-10-15 | S-1/A | S-1/A (amendment) | Oyster Point Pharma, Inc. | 0001193125-19-267294 ↗ |
| 2019-10-21 | S-1/A | S-1/A (amendment) | Oyster Point Pharma, Inc. | 0001193125-19-270374 ↗ |
| 2019-10-30 | EFFECT | EFFECT (declared effective) | Oyster Point Pharma, Inc. | 9999999995-19-002429 ↗ |
| 2019-10-31 | 424B4 | 424B4 (final prospectus) | Oyster Point Pharma, Inc. | 0001193125-19-280598 ↗ |
| 2020-05-12 | S-1 | S-1 (registration) | Oyster Point Pharma, Inc. | 0001193125-20-140387 ↗ |
| 2020-05-14 | S-1/A | S-1/A (amendment) | Oyster Point Pharma, Inc. | 0001193125-20-142919 ↗ |
| 2020-05-14 | S-1MEF | S-1MEF (added securities) | Oyster Point Pharma, Inc. | 0001193125-20-143095 ↗ |
| 2020-05-14 | EFFECT | EFFECT (declared effective) | Oyster Point Pharma, Inc. | 9999999995-20-001166 ↗ |
| 2020-05-18 | 424B4 | 424B4 (final prospectus) | Oyster Point Pharma, Inc. | 0001193125-20-144236 ↗ |
| 2020-11-16 | EFFECT | EFFECT (declared effective) | Oyster Point Pharma, Inc. | 9999999995-20-003193 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-10-21 | S-1/A | registration statement | $16.00–$18.00 | 5,000,000 | - | Nasdaq OYST | 3 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped, cover names 3 | document ↗ | |
| 2019-10-31 | 424B4 | final prospectus | $16.00 | 5,000,000 | $80,000,000 | Nasdaq OYST | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Ackermann Michael | Director | 4 | 2019–2020 | ||
| BASKETT FOREST | TenPercentOwner | 3 | 2019–2023 | ||
| Behbahani Ali | Director | 5 | 2019–2023 | ||
| Clare Ozawa | Director; Director,TenPercentOwner | 12 | 2019–2023 | ||
| Falcon Vision LLC | TenPercentOwner | 2 | 2019 | ||
| Florence Anthony A. Jr. | TenPercentOwner | 2 | 2019 | ||
| InvOpps GP IV, L.L.C. | Director,TenPercentOwner | 4 | 2019–2023 | ||
| InvOpps IV, L.P. | Director,TenPercentOwner | 4 | 2019–2023 | ||
| InvOpps IV US, L.P. | Director,TenPercentOwner | 4 | 2019–2023 | ||
| KKR Associates HCSG L.P. | TenPercentOwner | 2 | 2019 | ||
| KKR & Co. Inc. | TenPercentOwner | 2 | 2019 | ||
| KKR Fund Holdings GP Ltd | TenPercentOwner | 2 | 2019 | ||
| KKR Fund Holdings L.P. | TenPercentOwner | 2 | 2019 | ||
| KKR Group Holdings Corp. | TenPercentOwner | 2 | 2019 | ||
| KKR HCSG GP LLC | TenPercentOwner | 2 | 2019 | ||
| KKR Healthcare Strategic Growth Fund L.P. | TenPercentOwner | 2 | 2019 | ||
| KKR Management LLC | TenPercentOwner | 2 | 2019 | ||
| Kleiner Perkins Caufield & Byers XIV, LLC | TenPercentOwner | 2 | 2019 | ||
| KPCB XIV Associates, LLC | TenPercentOwner | 2 | 2019 | ||
| KPCB XIV Founders Fund, LLC | TenPercentOwner | 2 | 2019 | ||
| KRAVIS HENRY R | TenPercentOwner | 2 | 2019 | ||
| LAINOVIC SACHA | Director,TenPercentOwner | 4 | 2019–2023 | ||
| LINK WILLIAM J PHD | Director; Director,TenPercentOwner | 10 | 2019–2022 | ||
| Lochner Daniel | Officer | Chief Financial Officer | 16 | 2019–2023 | |
| MOTT DAVID M | TenPercentOwner | 2 | 2019 | ||
| Murray Mark Anthony | Director | 6 | 2019–2023 | ||
| Nau Jeffrey | Director,Officer | President and CEO | 14 | 2019–2023 | |
| NEA 14 GP, LTD | TenPercentOwner | 3 | 2019–2023 | ||
| NEA Partners 14, L.P. | TenPercentOwner | 3 | 2019–2023 | ||
| New Enterprise Associates 14, L.P. | TenPercentOwner | 3 | 2019–2023 | ||
| OYSTER POINT PHARMA I, LLC | TenPercentOwner | 2 | 2019 | ||
| ROBERTS GEORGE R | TenPercentOwner | 2 | 2019 | ||
| SANDELL SCOTT D | TenPercentOwner | 3 | 2019–2023 | ||
| Snisarenko John | Officer | Chief Commercial Officer | 7 | 2019–2022 | |
| Sonsini Peter W. | TenPercentOwner | 3 | 2019–2023 | ||
| Tsai Benjamin | Director | 5 | 2019–2023 | ||
| Versant Side Fund IV, L.P. | TenPercentOwner | 9 | 2019–2023 | ||
| Versant Vantage I GP-GP, LLC | TenPercentOwner | 9 | 2019–2023 | ||
| Versant Vantage I GP, L.P. | TenPercentOwner | 9 | 2019–2023 | ||
| Versant Vantage I, L.P. | TenPercentOwner | 9 | 2019–2023 | ||
| Versant Venture Capital IV, L.P. | TenPercentOwner | 9 | 2019–2023 | ||
| Versant Venture Capital VI, L.P. | TenPercentOwner | 9 | 2019–2023 | ||
| Versant Ventures IV, LLC | TenPercentOwner | 9 | 2019–2023 | ||
| Versant Ventures VI GP-GP, LLC | TenPercentOwner | 9 | 2019–2023 | ||
| Versant Ventures VI GP, L.P. | TenPercentOwner | 9 | 2019–2023 | ||
| Vida Ventures, LLC | TenPercentOwner | 2 | 2019 | ||
| WEISNER AIMEE S | Director | 6 | 2019–2023 | ||
| BARRIS PETER J | TenPercentOwner | 2 | 2019 | ||
| KERINS PATRICK J | TenPercentOwner | 2 | 2019–2023 | ||
| ATIEH MICHAEL G | Director | 5 | 2020–2023 | person page Fuzzy | |
| Eliades George Christopher | Director | 5 | 2021–2023 | ||
| Santel Donald J | Director | 4 | 2021–2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-02-27 | Oyster Point Pharma, Inc. | Pharmaceuticals | $92,999,999 | $84,999,985 | 7 | 1 |
| 2017-10-25 | Oyster Point Pharma, Inc. | Pharmaceuticals | $43,125,784 | $28,614,800 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Oyster Point Pharma, Inc. | NJ | State business registries | name and state |
| Federal award recipient | OYSTER POINT PHARMA, INC | NJ | Federal spending (USAspending) | name and state |
| Form D issuer | Oyster Point Pharma, Inc. | NJ | Form D private offerings | CIK (EXACT) |
| Paying company | Oyster Point Pharma, Inc. | NJ | Open Payments (drug and device company payments) | name and state |
| Patent assignee | Oyster Point Pharma, Inc. | NJ | Patents (USPTO) | name and state |
| SEC filer | Oyster Point Pharma, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Oyster Point Pharma, Inc. | NJ | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | OYSTER POINT PHARMA, INC. | EIN (EXACT) | ||
| Person page | Michael G Atieh | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NJ first:
- IGX CORP/DE NJ
- ADMA BIOLOGICS, INC. NJ
- Point of Care Nano-Technology, Inc. NJ
- Outlook Therapeutics, Inc. NJ
- Kalaris Therapeutics, Inc. NJ
- Tevogen Inc. NJ
- TAMIR BIOTECHNOLOGY, INC. NJ
- GENTA INC DE/ NJ
- BioNTech SE 2M
- Immatics N.V. 2M
In other datasets, the same topic (Health) in NJ:
- Nonprofit: 1ST CEREBRAL PALSY OF NEW JERSEY INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health